Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. N/A

    SBC: Alaphatech, Inc.            Topic: N/A

    N/A

    STTR Phase II 1999 Department of DefenseAir Force
  2. MULTI-DISCRIMINANT SENSING FROM HIGH ALTITUDE OR SPACE

    SBC: ALPHATECH, INC.            Topic: N/A

    N/A

    STTR Phase I 1999 Department of DefenseAir Force
  3. A Practical Method to Predict and Control Non-linear Aeroelasticity

    SBC: BEAM Technologies, Inc.            Topic: N/A

    N/A

    STTR Phase I 1999 Department of DefenseAir Force
  4. Self Consuming Satellite with Multi-Functional Structure

    SBC: Busek Co., Inc.            Topic: N/A

    N/A

    STTR Phase I 1999 Department of DefenseAir Force
  5. N/A

    SBC: GRADIENT TECHNOLOGY            Topic: N/A

    N/A

    STTR Phase II 1999 Department of DefenseAir Force
  6. Improving Laser Damage Threshold in ZnGeP2 using Motheye Antireflection Surface Relief Structures

    SBC: Holographic Lithographic            Topic: N/A

    N/A

    STTR Phase I 1999 Department of DefenseAir Force
  7. Nanograin, Quasicrystalline, Multiphase Coatings for Reduced Friction and Wear

    SBC: Spire Corporation            Topic: N/A

    N/A

    STTR Phase I 1999 Department of DefenseAir Force
  8. Novel Materials for Large, Deployable, Space Optics

    SBC: Triton Systems, Inc.            Topic: N/A

    N/A

    STTR Phase I 1999 Department of DefenseAir Force
  9. A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Cancer is the second leading cause of death after heart disease in the US Chemotherapy is a mainstay of treatment after surgical removal of tumors but the balance of clinical benefit versus disabling or life threatening side effects is often uncertain Genotyping of cancers to identify mutated oncogenes has enabled an era of targeted therapy Drugs targeting ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIDDK

    DESCRIPTION provided by applicant Non alcoholic steatohepatitis NASH is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosis and cirrhosis and high mortality rates NASH is frequently associated with other common metabolic abnormalities such as insulin resistance and visceral obesity Liver transplantation is curren ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government